Improved Healthcare Access Would Save Millions of Lives in Africa
Abstract
On June 18, 2025, the United States Food and Drug Administration approved Yeztugo (Lenacapavir), an antiretroviral medication for human immunodeficiency virus (HIV) prevention. However, for many people living in sub-Saharan Africa, healthcare access is nonexistent, and residents experience a higher HIV infection rate and a higher acquired immunodeficiency syndrome mortality rate, compared to people living in the USA. On September 4, 2025, the United States Department of State announced that it would facilitate extended access to the medicament lenacapavir for high HIV prevalence countries. However, more change is needed. More entities are required to help.
Fields of Study & Subjects
HIV/AIDS Research and Interventions
HIV/AIDS Impact and Responses
Pharmaceutical Economics and Policy
Publication details
- Journal / source
- International Journal of Translational Medical Research and Public Health
- Volume
- 10
- Pages
- e002–e002
- Publication date
- 1 January 2026
- Language
- EN